Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home Companies4D Molecular Therapeutics Inc

4D Molecular Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
12.71 USD -0.28 ( 2.16%)
Last update at 2026-11-12T15:41:00Z
VOLUME
95470
Market Cap
752.98M

Momentum Score

…

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.31
Low
12.86
High
52 Week Price Range
6.47
Low
16.93
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

4D Molecular Therapeutics is a clinical-stage biotechnology company that engineers adeno-associated viral (AAV) capsids to develop single-dose gene therapies with tissue-selective delivery. Long-term growth may be driven by clinical advancement of its pipeline, partnerships to deploy its capsid platform across ophthalmic, neurological and systemic indications, and broader adoption of gene therapy; investors may find the company attractive because the platform appears positioned to improve tissue targeting and could support lower dosing and differentiated safety profiles.
Key risks include clinical setbacks, manufacturing scale-up, regulatory uncertainty and significant financing needs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.99
Dividend Yield
-
Revenue TTM
92.01M
Revenue Per Share
1.42
Gross Profit TTM
-145.10M
Debt / Equity
0.04
ROE
-43.25%
Net Debt
-38.83M
ROCE
-30.52%
Diluted EPS TTM
-2.61

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -140.11M -160.87M -100.84M -107.49M -71.32M
Net income -140.11M -160.87M -100.84M -101.08M -68.30M
Selling general administrative 49.06M 46.58M 36.49M 32.91M 28.01M
Selling and marketing expenses - - 5.75M - -
Gross profit 77.58M 0.04M -76.37M 3.13M 18.04M
Reconciled depreciation 7.62M 6.71M 5.62M 3.88M 3.02M
Ebit -159.55M -187.84M -112.87M -113.91M -74.35M
Ebitda -151.92M -181.14M -108.66M -110.03M -71.33M
Depreciation and amortization 7.62M 6.71M 4.20M 3.88M 3.02M
Non operating income net other - - - 2.54M 0.02M
Operating income -159.55M -187.84M -112.87M -110.03M -71.33M
Other operating expenses 244.76M 187.88M 133.59M 113.16M 89.37M
Interest expense - - - 6.42M 3.04M
Interest income 19.48M 27.05M 9.17M 2.57M 0.14M
Net interest income 19.48M 27.05M 9.17M 2.57M 0.14M
Income tax expense - - 5.58M -6.42M -3.02M
Total revenue 85.21M 0.04M 20.72M 3.13M 18.04M
Total operating expenses 237.13M 187.88M 36.49M 113.16M 89.37M
Cost of revenue 7.62M 6.71M 97.10M - -
Total other income expense net 19.44M 26.97M 12.03M 2.54M 0.02M
Net income from continuing ops -140.11M -160.87M -95.93M -107.49M -71.32M
Net income applicable to common shares - - - -107.49M -71.32M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 566.71M 560.38M 339.89M 261.85M 353.49M
Other current assets 10.48M 10.05M 8.36M 6.96M 8.46M
Total liab 61.05M 49.78M 32.06M 30.51M 560.48M
Total stockholder equity 505.66M 510.61M 307.83M -314.49M -207.00M
Deferred long term liab - - - 0.21M 0.21M
Other current liab 26.87M 18.87M 12.01M 8.87M 7.74M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -716.30M -576.20M -415.33M -314.49M -207.00M
Other liab - - - 1.31M 2.83M
Other assets - - - 1.08M 0.60M
Cash 60.24M 149.34M 249.11M 218.64M 315.43M
Total current liabilities 43.98M 29.15M 18.95M 15.73M 16.34M
Current deferred revenue 0.36M 0.26M 0.27M 0.88M 2.60M
Net debt -38.83M -124.73M -234.44M -202.52M -298.98M
Short term debt 5.59M 5.64M 3.15M 2.65M 1.23M
Short long term debt total 21.41M 24.61M 14.67M 16.12M 16.45M
Other stockholder equity 1221.23M 1086.57M 723.14M 1.19M 0.42M
Property plant equipment - - - 22.26M 28.95M
Total current assets 413.13M 434.93M 296.59M 220.51M 315.43M
Long term investments 111.38M 80.58M 10.95M 4.91M 67.65M
Net tangible assets - - - 231.34M 319.11M
Short term investments 342.41M 275.54M 39.12M 161.20M 94.78M
Net receivables - - - 0.70M 0.05M
Inventory - - - - -8.50M
Accounts payable 11.16M 4.39M 3.52M 3.32M 4.76M
Accumulated other comprehensive income 0.73M 0.23M 0.02M -1.20M -0.42M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -314.49M -207.00M
Non currrent assets other 120.57M 4.26M 0.68M 1.08M -58.55M
Non current assets total 153.58M 125.45M 43.30M 41.34M 38.06M
Capital lease obligations 21.41M 24.61M 14.67M 16.12M 16.45M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -92.44M -302.44M 86.62M -5.51M -163.57M
Change to liabilities - - - 0.85M -12.44M
Total cashflows from investing activities -92.97M -302.44M 115.72M -17.05M -172.68M
Total cash from financing activities 112.96M 337.25M 156.83M 3.08M 118.09M
Change to operating activities - - - 3.38M -4.54M
Net income -140.11M -160.87M -100.84M -107.49M -71.32M
Change in cash -89.09M -99.77M 196.76M -100.65M -123.72M
Begin period cash flow 149.34M 249.11M 52.35M 153.00M 276.73M
End period cash flow 60.24M 149.34M 249.11M 52.35M 153.00M
Total cash from operating activities -109.08M -134.59M -75.79M -86.69M -69.13M
Issuance of capital stock 110.72M 331.41M 148.34M 0.00M 114.30M
Depreciation 7.62M 6.71M 5.75M 3.88M 3.02M
Other cashflows from investing activities -0.54M -3.79M 173.29M - -
Change to inventory - - - - -4.54M
Change to account receivables - - 0.00M 0.05M 1.44M
Sale purchase of stock 7.50M - - -0.47M 114.73M
Other cashflows from financing activities 112.96M 5.84M 8.49M 0.35M 3.79M
Change to netincome - - - 17.12M 14.70M
Capital expenditures 0.54M 3.79M 2.77M 11.54M 9.11M
Change receivables - - - 0.05M 1.44M
Cash flows other operating - - - -0.67M -18.36M
Cash and cash equivalents changes - - - -100.65M -123.72M
Change in working capital 6.17M 0.54M 0.63M -1.34M -15.53M
Stock based compensation 22.02M 26.12M 19.66M 17.12M 13.80M
Other non cash items -4.79M -7.08M -1.00M 1.14M 0.90M
Free cash flow -109.08M -138.37M -78.56M -98.22M -78.24M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FDMT
4D Molecular Therapeutics Inc		 -0.28
2.16%		 12.71 - - 8.18 1.86 4.75 -3.55
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

5858 Horton Street, EmeryVille, CA, United States, 94608

510 505 2680

https://www.4dmoleculartherapeutics.com

196

Name Title Year Born
Dr. John F. Milligan Ph.D. Exec. Chairman 1961
Dr. David H. Kirn M.D. Co-Founder, CEO & Director 1962
Ms. Theresa Janke Co-Founder & Chief of Staff 1975
Mr. August J. Moretti Esq., J.D. Chief Financial Officer 1951
Dr. Fred Kamal Ph.D. Pres & COO 1963
Mike Zanoni VP of Investor Relations NA
Dr. Scott P. Bizily J.D., Ph.D. Chief Legal & HR Officer and Corp. Sec. 1972
Dr. Robert S. Fishman Chief Medical Officer & Therapeutic Area Head of Pulmonology 1962
Dr. Raphael Schiffmann M.D. Sr. VP & Therapeutic Area Head of Cardiology NA
Dr. Robert Y. Kim M.B.A., M.D. Sr. VP & Clinical Therapeutic Area Head of Ophthalmology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…